Estimates Revisions Keymed Biosciences Inc.
Stocks
2162
KYG5252B1023
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 85.95 HKD | -1.32% |
|
+2.38% | +60.80% |
| 07-16 | Keymed Biosciences Expects Return to Profit in H1 | MT |
| 06-05 | Keymed Biosciences Receives $257 Million Upfront Payment After Gilead-Ouro Deal Close | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- 2162 Stock
- Consensus Keymed Biosciences Inc.
- Estimates Revisions
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
